IMAAVY (nipocalimab) Shows Over Two Years of Sustained Disease Control in Generalised Myasthenia Gravis

Nipocalimab Shows Sustained Efficacy in Generalised Myasthenia Gravis Over Two Years

Johnson & Johnson announced new long-term data from the Phase 3 Vivacity-MG3 study and its open-label extension (OLE) for nipocalimab (IMAAVY®) in antibody-positive adults with generalised myasthenia gravis (gMG). The data, presented at the American Academy of Neurology 2026 Meeting, reinforce nipocalimab's efficacy, sustained disease control, and safety profile over a maximum of 120 weeks of observation. Key findings include sustained clinical improvements in MG-ADL and QMG scores, reduction in total IgG, and incremental reduction in corticosteroid use, with half of patients achieving minimal symptom expression (MSE).

• Through 120 weeks in the open-label extension, nipocalimab demonstrated sustained improvements in MG-ADL and QMG scores, with mean reductions of 6.47 points (SE=1.20, p<0.001) and 5.97 points (SE=1.28, p<0.001) respectively. Over 64% reduction in total immunoglobulin G (IgG) was observed, and 57% of patients reduced corticosteroid use to low doses (≤10 or ≤5 mg/day). The safety profile remained consistent with no unexpected adverse events.
• Half of the patients (n=153) achieved minimal symptom expression (MSE), and nearly one-third (32%) achieved sustained MSE for at least 8 weeks. A post-hoc analysis showed that adults receiving nipocalimab plus standard of care were four times more likely to reach sustained MSE compared to those randomized to placebo (95% CI: 4.35 [1.37, 13.81], p=0.013).
• Patients who achieved sustained MSE experienced significantly greater improvements in day-to-day quality of life (MG-QoL-15r measure) compared to those with improvements that were not similarly sustained or among those who did not attain MSE. This highlights the clinical relevance of sustained symptom control for patient well-being in gMG.

Nipocalimab's Safety and Impact on Patient Quality of Life

Recent clinical studies have demonstrated promising therapeutic advances in generalized myasthenia gravis across multiple drug classes. These investigations encompass novel targeted therapies, complement inhibitors, and established immunosuppressive regimens, providing valuable insights into both efficacy and safety profiles for diverse patient populations.

• Telitacicept Bayesian Real-World Study (2026): Dual BAFF/APRIL inhibitor telitacicept (160-240 mg weekly subcutaneous) achieved 80% composite efficacy endpoint response in 15 evaluable patients, with significant improvements in MG-ADL (8.0±4.4 to 4.2±3.1, p<0.01) and QMG scores (13.8±5.5 to 7.6±4.3, p<0.01), plus substantial steroid-sparing effects (76% reduction in daily prednisone). Safety profile demonstrated only mild, transient adverse events with no serious events reported.

• Secukinumab versus Conventional Immunotherapy (2026): Anti-IL-17A monoclonal antibody secukinumab (150 mg/week×4 weeks, then monthly) in 35 AChR-positive gMG patients showed superior improvement rates versus controls at week 24 (QMG: 44.7% vs 27.5%, MG-ADL: 45.7% vs 25.8%, p<0.01), with rapid AChR antibody reduction (61.1% by week 4, 68.9% by week 24) and profound immunologic suppression of IL-17A (-84.1%), Th17 cells (-68.3%), and Tfh cells (-71.7%).

• Eculizumab Case Series for Refractory Ocular MG (2026): Complement C5 inhibitor eculizumab (900 mg weekly×4 weeks induction, then 1200 mg biweekly maintenance) in 5 AChR-positive refractory ocular/ocular-predominant MG patients demonstrated rapid symptom improvement within 1 week, with 4/5 patients achieving MGC≤2 and MG-ADL≤2 at 4 weeks and sustained control at 12 weeks, with no treatment-related adverse events observed.

• Efgartigimod in Very-Late-Onset GMG (2026): FcRn antagonist efgartigimod in 42 patients ≥65 years achieved 97.6% MG-ADL response rates at week 4 with 83.3% maintaining response at week 12, demonstrating mean response time of 6.37±5.46 days and significant prednisone dose reduction from median 20 mg/day to 10 mg/day, with excellent tolerability despite high comorbidity burden (88.1% had ≥1 comorbidity).

• Zilucoplan French Early Access Program (2026): Complement C5 inhibitor zilucoplan in 48 patients showed significant improvements in MG-ADL (7.4±4.4 to 2.5±2.7, p<0.0001), MMS-Garches scores (67.5±20.0 to 87.5±13.2, p<0.0001), and quality of life measures at 6 months, with notable reduction in MG crises (6 patients on treatment vs 22 in preceding 6 months) and 76% reduction in oral corticosteroid dose, though 15 patients experienced adverse events leading to discontinuation in 4 cases.

Nipocalimab's FcRn Mechanism and Competitive Landscape in gMG

Several FcRn inhibitors are being developed for generalized myasthenia gravis alongside nipocalimab, representing a promising class of therapeutics that prevent immunoglobulin recycling and rapidly reduce pathogenic antibody levels. These agents target the neonatal Fc receptor to enhance IgG catabolism, offering a novel therapeutic approach for autoantibody-mediated disorders.

Beyond gMG: Nipocalimab's Expanding Pipeline and Designations

Nipocalimab is being investigated across multiple IgG autoantibody- and alloantibody-mediated diseases beyond generalized myasthenia gravis. The drug's development program spans maternal-fetal medicine, autoimmune disorders, and various neurological conditions, with trials employing diverse intervention models ranging from placebo-controlled studies to active comparator designs.

• Hemolytic Disease of the Fetus and Newborn (HDFN) - The phase 3 AZALEA study employs a multicenter, randomized, placebo-controlled, double-blind design enrolling approximately 120 alloimmunized pregnant individuals at risk for severe HDFN. Participants are randomized 2:1 to receive intravenous 45 mg/kg nipocalimab or placebo weekly from 13-16 to 35 weeks gestational age, with postnatal follow-up extending 24 weeks for maternal participants and 104 weeks for neonates/infants.

• Sjögren's Disease - The completed DAHLIAS phase 2 trial utilized a double-blind, multicenter design across 69 centers in 10 countries, enrolling 163 participants with moderate-to-severe, active disease (ClinESSDAI ≥6) who were anti-Ro IgG autoantibody positive. Participants were randomized 1:1:1 to receive intravenous nipocalimab 5 mg/kg, 15 mg/kg, or placebo every 2 weeks for 22 weeks, with the 15 mg/kg group demonstrating significant reduction in ClinESSDAI score versus placebo.

• Rheumatoid Arthritis - The DAISY-RA phase 2a study investigated combination therapy using a 3:2 randomization of 103 participants with active RA despite advanced therapies to receive either nipocalimab (intravenous 30 mg/kg) plus certolizumab or certolizumab monotherapy every 2 weeks from weeks 0 to 24, with outcomes assessed through week 30.

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Nipocalimab is under investigation as a neonatal Fc receptor blocker for CIDP, with ongoing clinical trials examining its effectiveness, safety, and tolerability in this neurological condition alongside other FcRn inhibitors.

• Warm Autoimmune Hemolytic Anemia (wAIHA) - Development is based on nipocalimab's mechanism as a fully human IgG1 monoclonal antibody targeting FcRn, expected to reduce the half-life of pathogenic IgG autoantibodies responsible for wAIHA pathogenesis.

• Additional Neurological Indications - Clinical trials are underway investigating nipocalimab in myositis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease, representing expansion into multiple autoantibody-mediated neurological disorders.

Long-Term Data Solidifies Nipocalimab's Role in gMG

The latest long-term data for nipocalimab in generalized myasthenia gravis (gMG) marks a significant moment for patients and clinicians navigating this challenging autoimmune disorder. For a chronic condition like gMG, where symptoms fluctuate and long-term management is essential, evidence of sustained efficacy and a consistent safety profile over an extended period—up to 120 weeks—is invaluable. This data reinforces nipocalimab's role as a targeted therapy that specifically reduces pathogenic IgG autoantibodies by blocking the neonatal Fc receptor (FcRn), a mechanism that has revolutionized treatment options.

The findings from the Vivacity-MG3 study and its open-label extension are particularly compelling. Sustained improvements in key clinical measures like MG-ADL and QMG scores, coupled with a reduction in total IgG levels, underscore the drug's ability to provide meaningful disease control. Perhaps most impactful for patients is the reported incremental reduction in corticosteroid use and the achievement of minimal symptom expression (MSE) in half of the treated individuals. Reducing reliance on corticosteroids can significantly alleviate the burden of long-term side effects, while achieving MSE represents a substantial improvement in quality of life and functional independence.

However, the competitive landscape for gMG therapies is robust, with other approved FcRn inhibitors and complement inhibitors. While nipocalimab has secured its first approval in the US and is uniquely approved for MuSK-MG, some analyses have raised questions about its comparative efficacy against other targeted agents. This suggests that while the long-term data is positive, differentiation will be key. Furthermore, ongoing vigilance regarding the safety profile is necessary, as FcRn inhibitors can be associated with infections, and nipocalimab specifically has shown transient hypoalbuminemia and hypercholesterolemia. As with all novel, high-cost therapies for rare diseases, market access and reimbursement will remain critical considerations. Nevertheless, the sustained positive outcomes for nipocalimab not only strengthen its position in gMG but also validate the broader FcRn inhibition platform, supporting its development in other IgG-mediated conditions like HDFN and FNAIT.